Healthcare

According to a market report by Lucintel, the future of the plasma fractionation market looks promising with opportunities in hospitals & clinics and clinical research. The global plasma fractionation market is expected to reach an estimated $42.7 billion by 2028 with a CAGR of 7% from 2023 to 2028. The major drivers for this market are rising geriatric population, increasing prevalence of respiratory diseases, and growing use of immunoglobulin in different therapeutic applications.

In this market, albumin, immunoglobulin, coagulation factor, and protease inhibitor are the major segments by product. Lucintel forecasts that immunoglobulin will remain the largest product segment over the forecast period due to increasing prevalence of infections and disorders and it is extensively used for the treatment, diagnosis, and administration of metabolic diseases. 



Within this market, hospital & clinic is expected to remain the largest segment due to the extensive use of plasma fractionation among hospitals and clinics to treat various diseases. 



North America will remain the largest region due to an increase in the quantity of plasma collection facilities, rise in the demand for immunoglobulin, and growing number of elderly people with hereditary diseases in the region.

Grifols, CSL, Takeda Pharmaceutical, Octapharma, and Kedrion are the major suppliers in the global plasma fractionation market.



Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global plasma fractionation market by product, method, application, end use industry, and region. Lucintel has compiled a comprehensive research report entitled “Growth Opportunities in the Global Plasma Fractionation Market 2023-2028: Trends, Forecast, and Opportunity Analysis.” The Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global plasma fractionation market by product, method, application, end use industry, and region, as follows:

This more than 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or email us at helpdesk@lucintel.com.

 

Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. Lucintel offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.

 

Q.1. What are some of the most promising, high-growth opportunities for the plasma fractionation market by product (albumin, immunoglobulins, coagulation factors, protease inhibitors, and others), method (centrifugation, depth filtration, chromatography, and others), application (neurology, hematology, oncology, immunology, pulmonology, and others), end use industry (hospitals & clinics, clinical research, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?

Q.2. Which segments will grow at a faster pace and why?

Q.3. Which region will grow at a faster pace and why?

Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?

Q.5. What are the business risks and competitive threats in this market?

Q.6. What are the emerging trends in this market and the reasons behind them?

Q.7. What are some of the changing demands of customers in the market?

Q.8. What are the new developments in the market? Which companies are leading these developments?

Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?

Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?

Q.11. What M&A activity has occurred in the last five years and what has its impact been on the industry?